Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 24

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 24
---
 expectations presented in the forward-looking statements contained herein are reasonable at the time of filing, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, among other things:

| • |     | the possibility that the conditions to the closing of the Divestiture or the PIPE Financing are not satisfied (or                                                  
 waived), including the risk that required approvals from our stockholders for the Divestiture or the PIPE Financing are not obtained, on a timely basis or at all; |

| • |     | the occurrence of any event, change or other circumstance that could give rise to the right to terminate the                                                                                                                      
 Divestiture Agreement, including in circumstances requiring us to pay the termination fee to Kaken of $3.5 million, or the License Agreement, which would result in the loss of the non-refundable upfront payment of $6 million; |

| • |     | uncertainties as to the timing of the consummation of the Divestiture and the PIPE Financing and the ability of 
 each party to consummate such transactions;                                                                     |

| • |     | the nature, cost and outcome of any legal proceeding that may be instituted against us and others relating to the 
 Divestiture and the PIPE Financing;                                                                               |

| • |     | the effect of the announcement or pendency of the Divestiture and the PIPE Financing on our business partners or                         
 other business relationships, customers, operating results and business generally, and the response of competitors to such transactions; |

| • |     | possible disruption related to the Divestiture or the License Agreement to our ongoing business operations and                                                                  
 opportunities, including risks related to the diversion of the time and attention of our management or employees during the pendency of the Divestiture and the PIPE Financing; |

| • |     | risks that the pendency of the Divestiture and the PIPE Financing affects our current operations or our ability 
 to retain or recruit employees;                                                                                 |

| • |     | the amount of the costs, fees, expenses and charges related to the Divestiture, Divestiture Agreement, PIPE 
 Financing and License Agreement;                                                                            |

| • |     | the risk that our stock price may fluctuate during the pendency of the Divestiture and the